A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer
| Autor: | Jaafar Bennouna, V. Trillet-Lenoir, J. Berille, Alain Rivière, Etienne Lemarié, A. Monnier, Bernard Milleron, Jean-Yves Douillard, K Soussan-Lazard |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Neutropenia Paclitaxel medicine.medical_treatment Population Docetaxel Vinorelbine Vinblastine Gastroenterology Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans education Survival rate Aged Neoplasm Staging Chemotherapy education.field_of_study business.industry Combination chemotherapy Middle Aged medicine.disease Survival Rate Treatment Outcome Female Taxoids business Febrile neutropenia medicine.drug Follow-Up Studies |
| Zdroj: | European journal of cancer (Oxford, England : 1990). 36(9) |
| ISSN: | 0959-8049 |
| Popis: | A phase II study was conducted to determine the efficacy and the safety of docetaxel combined with vinorelbine as first-line chemotherapy in patients with metastatic or unresectable non-small cell lung cancer (NSCLC). 39 patients, median age 54 years (range: 35–69), with stage IIIB (5 patients; 13%) or IV (34 patients; 87%) NSCLC were treated with 75 mg/m2 docetaxel given intravenously (i.v.) over 1 h on day 1 and with 20 mg/m2 vinorelbine given i.v. over 15 to 30 min on days 1 and 5. Cycles were repeated every 3 weeks. 9 of the 39 patients had a partial response (overall response rate 23.1%, 95% confidence interval (CI): 11.1–39.3%) with a median duration of response of 20 weeks (95% CI; 17–30). The median survival was 40 weeks (95% CI: 21–49 weeks) with a 1-year survival rate of 31% in the intent-to-treat population. Neutropenia grade IV occurred in 33 patients (92%). 16 patients (41%) experienced febrile neutropenia with a concomitant stomatitis in 9 patients (23%). One patient died due to febrile neutropenia associated with a grade 4 stomatitis and 1 patient due to a septicaemia concomitant with a grade 4 neutropenia. Although the combination of docetaxel and vinorelbine is feasible, the efficacy does not seem to be improved compared with single-agent docetaxel or vinorelbine and the rate of febrile neutropenia is unacceptable in this population with incurable disease. Therefore, different doses and/or schedules are to be explored. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect